Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16719229 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL31240235 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL16323750 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL17296020 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL8033386 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL25168218 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL8507410 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL3988979 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL22029385 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL934152 | 0.98 | TDP1 (0.50) | TDP1GPR84FFAR1FFAR4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044886-B | Production method of polycaprolactone | 青岛科技大学 | 2023-08-29 | — | — | CN | claimed |
| CN-114044886-A | Production method of polycaprolactone | 青岛科技大学 | 2022-02-15 | — | — | CN | claimed |
| US-4535179-A | Synthesis of bicyclic and tricyclic 7-oxa prostaglandin endoperoxide analogs via oxypalladation of norbornadiene | IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC. (US) | 1985-08-13 | — | — | US | claimed |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4737436-A1 | CATIONIC LIPID CONTAINING TWO TERTIARY AMINE GROUPS, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | PFIZER (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4612129-A1 | LIPID COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-0630369-B1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS | PFIZER LTD (GB) | 1997-06-04 | — | — | EP | disclosed |
| US-5607691-A | IONTOPHORESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-03-04 | — | — | US | disclosed |
| US-5468765-A | Benzimidazole anthelmintic agents | PFIZER INC. (US) | 1995-11-21 | — | — | US | disclosed |
| US-5455032-A | Immunoprotection against infections | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| EP-0630369-A1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS. | PFIZER LTD (GB) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
| WO-1993018010-A1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS | PFIZER LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
| US-4535179-A | Synthesis of bicyclic and tricyclic 7-oxa prostaglandin endoperoxide analogs via oxypalladation of norbornadiene | IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC. (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TDP1 2024/4885GPR84 3439/4885FFAR1 4442/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | TDP1 4012/4885GPR84 2969/4885FFAR1 629/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | TDP1 1693/4885GPR84 4704/4885FFAR1 2676/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | TDP1 1854/4885GPR84 3015/4885FFAR1 4028/4885 |
| US-20250367129-A1 | Lipid Compounds and Uses Thereof | POLN, PHOSPHO1, NPC1 | TDP1 1138/4885GPR84 3261/4885FFAR1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.